Momenta Phama (MNTA) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stifel Cuts PT on Momenta Pharma (MNTA) to $20; Glatopa Court Battle Becomes Increasingly Important
February 18, 2016 2:41 PM ESTStifel trims its price target on Buy-rated Momenta Pharmaceuticals (Nasdaq: MNTA) from $29 to $20 following Q4 results reported earlier Thursday.
Analyst Thomas Shrader commented: Momenta reported 4Q15 GLATOPA revenues of $15.6 million, and $43.6 million for the year 2015, resulting in an EPS of $(0.43) for the... More
